A review of analytical method development and validation of labetalol hydrochloride

Combined alpha- and beta-adrenoceptor blockers, such as labetalol hydrochloride, are administered orally and intravenously to treat hypertension. It is a competitive antagonist of postsynaptic nascent 1adrenoceptors and an unselective antagonist of beta-adrenoceptors. It is a medication used to treat hypertension. A significant amount of research has been conducted on the synthesis, pharmacology, mechanism of action, and other aspects of labetalol hydrochloride. However, the authors of this paper have only addressed the analytical methodologies that have been published, thus far for the estimation of labetalol hydrochloride in pharmaceutical dosage forms. Reviewing various analytical techniques and validating the related substance of labetalol hydrochloride is the main goal of this article.